Semaglutide

Overview

Semaglutide is an acylated synthetic analog of glucagon-like peptide-1 (GLP-1) with 94% sequence homology to native human GLP-1. Engineered with a C-18 fatty acid chain that enables albumin binding, Semaglutide achieves an extended half-life of approximately 7 days, allowing for once-weekly research dosing protocols.

As one of the most extensively studied GLP-1 receptor agonists, Semaglutide has been the subject of multiple large-scale clinical trial programs (SUSTAIN, STEP, SELECT, PIONEER) investigating its effects on glucose homeostasis, body weight regulation, and cardiovascular outcomes.

The peptide's mechanism operates through multiple complementary pathways including pancreatic beta-cell stimulation, appetite center modulation in the hypothalamus, and delayed gastric emptying.

Chemical Profile

Mechanism of Action

Semaglutide activates the GLP-1 receptor (GLP-1R), a class B G protein-coupled receptor expressed in pancreatic islet cells, the gastrointestinal tract, the cardiovascular system, and the central nervous system. Upon binding, it activates the Gs/adenylyl cyclase/cAMP/PKA cascade, leading to glucose-dependent insulin secretion from pancreatic beta cells.

The C-18 fatty diacid side chain (attached at Lys26 via a linker) enables non-covalent binding to serum albumin, which serves as a circulating reservoir. This albumin binding reduces renal clearance and protects against DPP-IV degradation, extending the half-life to ~168 hours.

In the CNS, Semaglutide crosses the blood-brain barrier to act on GLP-1R-expressing neurons in the hypothalamic arcuate nucleus and other appetite-regulating centers, reducing hunger signaling and promoting satiety. It also acts on the brainstem to delay gastric emptying, contributing to reduced caloric intake.

Research Applications

• GLP-1 receptor activation and signaling
• Glucose homeostasis and insulin secretion
• Appetite regulation and satiety signaling
• Pancreatic beta-cell function and preservation
• Cardiovascular risk reduction mechanisms
• Weight management pharmacology
• Neuroprotective effects of GLP-1R agonism

Handling & Reconstitution

1. 1Allow the vial and sterile water to reach room temperature (15–25°C).
2. 2Using a sterile syringe, withdraw the appropriate volume of sterile water.
3. 3Inject the water slowly along the inside wall of the vial — do not spray directly onto the powder.
4. 4Gently swirl the vial until the powder is fully dissolved. Do not shake vigorously.
5. 5Once reconstituted, store at 2°C – 8°C. Protect from light.
6. 6Use within 28 days after reconstitution.
7. 7Do not freeze reconstituted solution.